Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Zometa
Zometa 4 mg powder and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-108440 · Präparat HOS-093013
Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop
diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) calcitonin (HOS-108441)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-29T09:40:00Z · SHA-256 c9c7b7b9008f66cb09fb660f030ac42163dc8944992c72a8ce016d546a637a58 · Passage 4d4c14d632f7c74bed461cbf78f3bcbabb0e7cfa9f9852ee0c4e2035e0a21e89 · Zeichen 389–590 im Abschnitt
Wechselwirkungen · Zometa
Zometa 4 mg/5 ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 25
HOS-108467 · Präparat HOS-093013
Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop
diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for
longer periods than required (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) calcitonin (HOS-108441)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-29T09:40:00Z · SHA-256 c9c7b7b9008f66cb09fb660f030ac42163dc8944992c72a8ce016d546a637a58 · Passage 70053d1ecaea71e32bc81319d0f3cdcaf06240089f65dab76de0a4b11a29cbcf · Zeichen 389–638 im Abschnitt
Wechselwirkungen · Zometa
Zometa 4 mg/100 ml solution for infusion · Abschnitt 4.5 · PDF-Seite 43
HOS-108491 · Präparat HOS-093013
Caution is advised when bisphosphonates are administered with aminoglycosides, calcitonin or loop
diuretics, since these agents may have an additive effect, resulting in a lower serum calcium level for
longer periods than required (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) calcitonin (HOS-108441)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-29T09:40:00Z · SHA-256 c9c7b7b9008f66cb09fb660f030ac42163dc8944992c72a8ce016d546a637a58 · Passage 70053d1ecaea71e32bc81319d0f3cdcaf06240089f65dab76de0a4b11a29cbcf · Zeichen 389–638 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 20–21
HOS-108905 · Präparat HOS-093083
20
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be
AUC: ↑ 4-fold used with co-administration of
Due to CYP3A inhibition by Kaletra and parenteral midazolam.
lopinavir/ritonavir If Kaletra is co-administered with
parenteral midazolam, it should be
done in an intensive care unit (ICU)
or similar setting which ensures
close clinical monitoring and
appropriate medical management in
case of respiratory depression
and/or prolonged sedation. Dosage
adjustment for midazolam should be
considered especially if more than a
single dose of midazolam is
administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended
(see section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, and Felodipine, Nifedipine, Clinical monitoring of therapeutic
Nicardipine Nicardipine: and adverse effects is
Concentrations may be increased recommended when these
due to CYP3A inhibition by medicines are concomitantly
lopinavir/ritonavir. administered with Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when
due to CYP3A induction by these medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 07de481e5f74c75a6211a29709c221ad50916e1780e215eb7341382e9a6c287a · Zeichen 41905–45409 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 56–57
HOS-109016 · Präparat HOS-093083
56
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be used
AUC: ↑ 4-fold with co-administration of Kaletra and
Due to CYP3A inhibition by parenteral midazolam. If Kaletra is
lopinavir/ritonavir co-administered with parenteral
midazolam, it should be done in an
intensive care unit (ICU) or similar
setting which ensures close clinical
monitoring and appropriate medical
management in case of respiratory
depression and/or prolonged sedation.
Dosage adjustment for midazolam
should be considered especially if
more than a single dose of midazolam
is administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and sinus
tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended (see
section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic
and Nicardipine Nicardipine: and adverse effects is recommended
Concentrations may be increased when these medicines are
due to CYP3A inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when these
due to CYP3A induction by medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage bbdb1518d507ab9bf3037f812d7ca4e3f06d2a449a3a956237657f28f1c80c69 · Zeichen 40688–43969 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 91–92
HOS-109092 · Präparat HOS-093083
91
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and pimozide is
of pimozide are expected to contraindicated as it may increase
increase. the risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and quetiapine is
of quetiapine are expected to contraindicated as it may increase
increase. quetiapine-related toxicity.
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be
AUC: ↑ 4-fold used with co-administration of
Due to CYP3A inhibition by Kaletra and parenteral midazolam.
lopinavir/ritonavir If Kaletra is co-administered with
parenteral midazolam, it should be
done in an intensive care unit (ICU)
or similar setting which ensures
close clinical monitoring and
appropriate medical management in
case of respiratory depression
and/or prolonged sedation. Dosage
adjustment for midazolam should be
considered especially if more than a
single dose of midazolam is
administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and sinus
tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended (see
section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic
and Nicardipine Nicardipine: and adverse effects is recommended
Concentrations may be increased when these medicines are
due to CYP3A inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when
due to CYP3A induction by these medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) pimozide (HOS-085600) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 703aea6daa39d7a84dcc105bf1c63b26907c5686341c713d7b68e5df123b8727 · Zeichen 40354–44819 im Abschnitt
Wechselwirkungen · Tamiflu
Tamiflu 30 mg hard capsules Tamiflu 45 mg hard capsules Tamiflu 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-110031 · Präparat HOS-093293
Additional information
No pharmacokinetic interactions between oseltamivir or its major metabolite have been observed
when co-administering oseltamivir with paracetamol, acetylsalicylic acid, cimetidine, antacids
(magnesium and aluminium hydroxides and calcium carbonates), rimantadine or warfarin (in subjects
stable on warfarin and without influenza).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) calcium (HOS-085615) magnesium (HOS-085165) warfarin (HOS-085950) rimantadine (HOS-110033)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T13:27:00Z · SHA-256 49e3275593869eab140681f5cba3d7da7ff895500b27bac431ac12de5f5745b2 · Passage 2313176ea584e794ff01fb67ca636732f3c48aee7c2f781266db543c4d256970 · Zeichen 1273–1626 im Abschnitt
Wechselwirkungen · Tamiflu
Tamiflu 6 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 35
HOS-110068 · Präparat HOS-093293
Additional information
No pharmacokinetic interactions between oseltamivir or its major metabolite have been observed
when co-administering oseltamivir with paracetamol, acetylsalicylic acid, cimetidine, antacids
(magnesium and aluminium hydroxides and calcium carbonates), rimantadine or warfarin (in subjects
stable on warfarin and without influenza).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) calcium (HOS-085615) magnesium (HOS-085165) warfarin (HOS-085950) rimantadine (HOS-110033)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T13:27:00Z · SHA-256 49e3275593869eab140681f5cba3d7da7ff895500b27bac431ac12de5f5745b2 · Passage 2313176ea584e794ff01fb67ca636732f3c48aee7c2f781266db543c4d256970 · Zeichen 1331–1684 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-110226 · Präparat HOS-093339
Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold,
respectively, indicating an inhibition of the CYP3A4 by imatinib. Therefore, caution is recommended
when administering Glivec with CYP3A4 substrates with a narrow therapeutic window (e.g.
cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil,
terfenadine, bortezomib, docetaxel and quinidine). Glivec may increase plasma concentration of other
CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers,
certain HMG-CoA reductase inhibitors, i.e. statins, etc.).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) simvastatin (HOS-086158) quinidine (HOS-085593) calcium (HOS-085615) docetaxel (HOS-084505) tacrolimus (HOS-085202) bortezomib (HOS-110227) pimozide (HOS-085600) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 90b6daf3cde987b8bbe424a8160367717eb0bce2aefbeba57f482ac99a1a5df9 · Zeichen 1905–2538 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 40 mg/12.5 mg tablets MicardisPlus 80 mg/12.5 mg tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-110399 · Präparat HOS-093371
Calcium salts
Thiazide diuretics may increase serum calcium levels due to the decreased excretion. If calcium
supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum
calcium levels should be monitored and calcium dose adjusted accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) vitamin D (HOS-086114)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 0dfef4aac30332e0190dc113490ce9dc33bf6ed064c4dabfe70d0c0b8c327622 · Zeichen 6019–6303 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 80 mg/25 mg tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-110448 · Präparat HOS-093371
Calcium salts
Thiazide diuretics may increase serum calcium levels due to the decreased excretion. If calcium
supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed, serum
calcium levels should be monitored and calcium dose adjusted accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) vitamin D (HOS-086114)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 0dfef4aac30332e0190dc113490ce9dc33bf6ed064c4dabfe70d0c0b8c327622 · Zeichen 6021–6305 im Abschnitt
Wechselwirkungen · Forsteo
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 4
HOS-111023 · Präparat HOS-093433
In a study of 15 healthy subjects administered digoxin daily to steady state, a single FORSTEO dose
did not alter the cardiac effect of digoxin. However, sporadic case reports have suggested that
hypercalcaemia may predispose patients to digitalis toxicity. Because FORSTEO transiently increases
serum calcium, FORSTEO should be used with caution in patients taking digitalis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:20:00Z · SHA-256 1571e886a5969a7f43ca0235f8b0a587a54392572741cea41fd72e7028e88f2e · Passage e255e8940d635da9276c3cc25a0f74878d9c45a5f9b5669e14302c0adb27af5b · Zeichen 0–376 im Abschnitt
Wechselwirkungen · Forsteo
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 4
HOS-111025 · Präparat HOS-093433
Co-administration of raloxifene or hormone replacement therapy with FORSTEO did not alter the
effects of FORSTEO on serum or urine calcium or on clinical adverse events.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): raloxifene (HOS-088361) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:20:00Z · SHA-256 1571e886a5969a7f43ca0235f8b0a587a54392572741cea41fd72e7028e88f2e · Passage bd3cfacb812682134e7c3e3b08167872fe0ff6a744a9a6f0a284a584e55e83f5 · Zeichen 522–691 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111255 · Präparat HOS-093485
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) doxazosin (HOS-088800) calcium (HOS-085615) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage cabfad89c45f22b6c41a39f145cc850ce5c6ddf73cc1063f85fcb928cb8d0481 · Zeichen 2943–3697 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111258 · Präparat HOS-093485
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy
subjects. In study subjects whose blood pressure was not controlled, the reduction was greater
although this reduction was not associated with hypotensive symptoms in the majority of subjects. In
patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a
blood pressure decrease, which (with the exception of alpha blockers -see above-) is, in general, minor
and not likely to be clinically relevant. Analysis of phase 3 clinical trial data showed no difference in
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 1df1359c9bc444a4301229f9fa020c4c04fef72f71cca7d6a70230e986333d2b · Zeichen 3699–5380 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20–21
HOS-111302 · Präparat HOS-093485
20
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) doxazosin (HOS-088800) calcium (HOS-085615) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 999d333c830ddb852b21bf2047f283bfeae5cc46ae36b00f2f883395cebd5d4c · Zeichen 2942–3700 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-111303 · Präparat HOS-093485
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy
subjects. In study subjects whose blood pressure was not controlled, the reduction was greater
although this reduction was not associated with hypotensive symptoms in the majority of subjects. In
patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a
blood pressure decrease, which (with the exception of alpha blockers -see above-) is, in general, minor
and not likely to be clinically relevant. Analysis of phase 3 clinical trial data showed no difference in
adverse events in patients taking tadalafil with or without antihypertensive medicinal products.
However, appropriate clinical advice should be given to patients regarding a possible decrease in
blood pressure when they are treated with antihypertensive medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage c0ae8045aff7f8a7fd05a121cf691a3f593453fda4a2a84d3dbb9c19b2f51831 · Zeichen 3702–5657 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-111341 · Präparat HOS-093485
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) doxazosin (HOS-088800) calcium (HOS-085615) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage cabfad89c45f22b6c41a39f145cc850ce5c6ddf73cc1063f85fcb928cb8d0481 · Zeichen 2946–3700 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-111342 · Präparat HOS-093485
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy
subjects. In study subjects whose blood pressure was not controlled, the reduction was greater
although this reduction was not associated with hypotensive symptoms in the majority of subjects. In
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 9904fece13ee6f6b129a6a22aedb04cd335a2be1fc9883142186e6b2fc89641b · Zeichen 3702–5076 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 19–20
HOS-112103 · Präparat HOS-093615
19
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
Calcium channel blockers
Bepridil REYATAZ should not be used in Co-administration with bepridil is
combination with medicinal products that contraindicated (see section 4.3)
are substrates of CYP3A4 and have a
narrow therapeutic index.
Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of
(atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is recommended,
Diltiazem Cmin: ↑142% (↑114% ↑173%) with subsequent titration as needed
and ECG monitoring.
Desacetyl-diltiazem AUC: ↑165% (↑145%
↑187%)
Desacetyl-diltiazem Cmax: ↑172% (↑144%
↑203%)
Desacetyl-diltiazem Cmin: ↑121% (↑102%
↑142%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) bepridil (HOS-085612) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage a5938ef1523f856eb59b74422c7cfaea01c48399a19f2b7a8ea958d4d8e50ef3 · Zeichen 51161–52517 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.